Akihiro Inano

463 total citations
13 papers, 359 citations indexed

About

Akihiro Inano is a scholar working on Oncology, Pharmacology and Epidemiology. According to data from OpenAlex, Akihiro Inano has authored 13 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pharmacology and 3 papers in Epidemiology. Recurrent topics in Akihiro Inano's work include Drug Transport and Resistance Mechanisms (4 papers), Amino Acid Enzymes and Metabolism (3 papers) and Metabolism and Genetic Disorders (3 papers). Akihiro Inano is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Amino Acid Enzymes and Metabolism (3 papers) and Metabolism and Genetic Disorders (3 papers). Akihiro Inano collaborates with scholars based in Japan, United States and United Kingdom. Akihiro Inano's co-authors include Ikumi Tamai, Yoshimichi Sai, Akira Tsuji, Hiroko Nikaido, Yuichi Sugiyama, Masahide Asano, Hiroyuki Kusuhara, Rikiya Ohashi, Kazuya Maeda and Jun‐ichi Nezu and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology and Journal of Pharmaceutical Sciences.

In The Last Decade

Akihiro Inano

13 papers receiving 348 citations

Peers

Countries citing papers authored by Akihiro Inano

Since Specialization

Citations

This map shows the geographic impact of Akihiro Inano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihiro Inano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihiro Inano more than expected).

Fields of papers citing papers by Akihiro Inano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihiro Inano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihiro Inano. The network helps show where Akihiro Inano may publish in the future.

Co-authorship network of co-authors of Akihiro Inano

This figure shows the co-authorship network connecting the top 25 collaborators of Akihiro Inano. A scholar is included among the top collaborators of Akihiro Inano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihiro Inano. Akihiro Inano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma 2021 ·Current Oncology ·Masazumi Fujii, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi, Takashi Tamiya, (unknown), Soichi Oya, Fumiaki Takahashi, Taku Sato, (unknown), (unknown)	9
2	Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor 2020 ·Drug Research ·Haruki Yamada, Hiromasa Ohira, (unknown), Kōichi Nakamura, Atsushi Takahashi, Kazumichi Abe, Akihiro Inano, (unknown), (unknown), Tomohisa Saito, Yasuhiro Ohba, Kimio Terao, Akihiro Ohnishi	2
3	Determination of the Kinetic Parameters for 123I Uptake by the Thyroid, Thyroid Weights, and Thyroid Volumes in Present-day Healthy Japanese Volunteers 2019 ·Health Physics ·Takashi Kudo, Akihiro Inano, Sanae Midorikawa, Hitoshi Kubo, (unknown), (unknown), Chizu Fukushima, Kazuya Maeda, Noboru Oriuchi, Shin Irie, Shunichi Yamashita, Hiroyuki Kusuhara	5
4	Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects 2017 ·Drug Metabolism and Pharmacokinetics ·Hiroyuki Kusuhara, Tadayuki Takashima, Hisako Fujii, Tsutomu Takashima, Masaaki Tanaka, Akira Ishii, Shusaku Tazawa, Kazuhiro Takahashi, Kayo Takahashi, (unknown), T. Yano, Makoto Kataoka, Akihiro Inano, Suguru Yoshida, Takamitsu Hosoya, Yuichi Sugiyama, Shinji Yamashita, (unknown), Yasuyoshi Watanabe	6
5	An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development 2015 ·Journal of Pharmaceutical Sciences ·Shinji Yamashita, Makoto Kataoka, Yuki Suzaki, Hiromitsu Imai, Takuya Morimoto, Kyoichi Ohashi, Akihiro Inano, (unknown), (unknown), Yuichi Sugiyama	10
6	Dosing time‐dependent effect of raloxifene on plasma plasminogen activator inhibitor‐1 concentrations in post‐menopausal women with osteoporosis 2013 ·Clinical and Experimental Pharmacology and Physiology ·Hitoshi Ando, Toshiki Otoda, (unknown), Yukihiro Nagai, Akihiro Inano, Toshinari Takamura, Kentaro Ushijima, Keiko Hosohata, Eiki Matsushita, Tetsuo Saito, Shuichi Kaneko, Akio Fujimura	10
7	Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as anin vivoinhibitor of BCRP 2012 ·British Journal of Pharmacology ·Hiroyuki Kusuhara, Hidetoshi Furuie, Akihiro Inano, (unknown), (unknown), Chunyong Wu, (unknown), (unknown), Ichiro Ieiri, Mariko Morishita, (unknown), Hiroshi Mayahara, Takuya Fujita, Kazuya Maeda, Yuichi Sugiyama	111
8	The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans 2012 ·European Journal of Clinical Pharmacology ·Yuki Suzaki, Naoto Uemura, Makoto Takada, Tetsuji Ohyama, (unknown), Takuya Morimoto, Hiromitsu Imai, (unknown), Akihiro Inano, Masakiyo Hosokawa, (unknown), Kyoichi Ohashi	27
9	Effect of Milk on the Pharmacokinetics of Oseltamivir in Healthy Volunteers 2011 ·Journal of Pharmaceutical Sciences ·Kaori Morimoto, (unknown), (unknown), (unknown), Yoichiro Ogama, (unknown), (unknown), (unknown), (unknown), Akihiro Inano, Takashi Kano, Ikumi Tamai, Takuo Ogihara	27
10	Functional Regions of Organic Cation/Carnitine Transporter OCTN2 (SLC22A5): Roles in Carnitine Recognition 2004 ·Drug Metabolism and Pharmacokinetics ·Akihiro Inano, Yoshimichi Sai, Yukio Kato, Ikumi Tamai, Masaji Ishiguro, Akira Tsuji	16
11	Acetyl‐L‐carnitine permeability across the blood–brain barrier and involvement of carnitine transporter OCTN2 2003 ·Biopharmaceutics & Drug Disposition ·Akihiro Inano, Yoshimichi Sai, Hiroko Nikaido, (unknown), Masahide Asano, Akira Tsuji, Ikumi Tamai	65
12	Studies on Functional Sites of Organic Cation/Carnitine Transporter OCTN2 (SLC22A5) Using a Ser467Cys Mutant Protein 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Rikiya Ohashi, Ikumi Tamai, Akihiro Inano, (unknown), Yoshimichi Sai, Jun‐ichi Nezu, Akira Tsuji	55
13	Microdialysis studies of the middle ear distribution kinetics of amoxicillin in the awake chinchilla 2001 ·Journal of Pharmaceutical Sciences ·Yue Huang, Ping Ji, Akihiro Inano, Zheng Yang, G. Scott Giebink, Ronald J. Sawchuk	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact